

DAFTAR PUSTAKA

- Adeloye, D., Song, P., Zhu, Y, Campbell, H., Sheikh, A., & Rudan, I., 2022, Global, Regional, and National Prevalence of, and Risk Factor for Chronic Obstructive Pulmonary Disease (COPD) in 2019: a Systematic Review and Modeling Analysis, *Lancet Respiratory Medicine*, 10(5): 447-458.
- Aghili, M., Vahidi, E., Mohammadrezaei, N., Mirraji, T., & Abedini, A., 2020, Effectiveness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; A Randomized Clinical Trial, *Archives of Academic Emergency Medicine*, 8(1): e85.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, 2013, *Riset Kesehatan Dasar*, Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI, Jakarta.
- Barr, R.G., Rowe, B.H., & Camargo, C.A., 2003, Methylxantines for Exacerbations of Chronic Obstructive Pulmonary Disease: Meta-Analysis of Randomised Trials, *British Medical Journal*, 327(7416): 643.
- Carruthers, S.G., Hoffman, B.B., Melmon, K.L., & Nierenberg, D.W., 2000, *Clinical Pharmacology: Basic Principles in Therapeutics*, Fourth Edition, 265-269, McGraw Hill, New York.
- Cazzola, M., Calzetta, L., Page, C., Jardim, J., Chuchalin, A.G., Rogliani, P., & Matera, M.G., 2015, Influence of N-acetylcysteine on Chronic Bronchitis or COPD Exacerbations: A Meta-analysis, *European Respiratory Review*, 24: 451-461.
- Charlson, M.E., Pompei, P., Ales, K.L., & MacKenzie, C.R., 1987, New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation, *Journal of Chronic Disease*, 40(5): 373-383.
- Dahlan, M.S., 2010, *Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*, 32, 136-140, Salemba Medika, Jakarta.
- Dalal, A.A., Christensen, L., Liu, F., Riedel, A.A., 2010, Direct Costs of Chronic Obstructive Pulmonary Disease among Managed Care Patients, *International Journal of Chronic Obstructive Pulmonary Disease*, 5: 341-149.

- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., & Ellingrod, V., 2020, *Pharmacotherapy: A Pathophysiologic Approach*, Eleventh Edition, McGraw Hill, New York.
- DiPiro, J.T., Talbert, R.L., Yeas, G.C., Matzke, G.R., Wells, B.G., & Posey, L.M., 2005, *Pharmacotherapy: A Pathophysiologic Approach*, Sixth Edition, 537-554, McGraw Hill, New York.
- Durham, M.C., 2004, Tiotropium (Spiriva): a Once Daily Inhaled Anticholinergic Medication for Chronis Obstructive Pulmonary Disease, *BUMC Proceedings*, 17: 366-371.
- Emre, C.J., Ozdemir, O., Baysak, A., Aksoy, U., Ozdemir, P., Oz, A.T., & Deniz, S., 2015, Clinical Factors Affecting the Cost of Hospitalized Chronic Obstructive Pulmonary Disease Exacerbations, *Eurasian Journal Pulmonol*, 16: 180-183.
- Ferreira, I.M., Brooks, D., Lacasse, Y., & Goldstein, R.S., 2000, Nutritional Support for Individuals with COPD: a Meta-analysis, *Chest Journal*, 117(3): 672-8.
- Fishman, A.P., 2008, *Fishman's Pulmonary Disease and Disorders*, Fourth Edition, 707-708, 711, 731, 741-743, McGraw Hill, New York.
- Freo, U., Ruocco, C., Valerio, A., Scagnol, I., & Nisoli, E., 2021, Paracetamol: A Review of Guideline Recommendations, *Journal of Clinical Medicine*, 10(15): 3420.
- Global Initiative for Chronic Obstructive Lung Disease, 2017, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, 2017 Report, Global Initiative for Chronic Obstructive Lung Disease Inc.
- Global Initiative for Chronic Obstructive Lung Disease, 2022, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease*, 2022 Report, Global Initiative for Chronic Obstructive Lung Disease Inc.

- Gohlke, P., Jurgensen, T., von Kugelgen, S., & Unger, T., 1999, Candesartan Cilexetil: Development and Preclinical Studies, *Drugs of Today*, 35(2): 105-115.
- Hilleman, D.E., Dewan, N., Malesker, M. & Friedman, M., 2000, Pharmacoeconomic Evaluation of COPD, *Chest*, 118(5): 1278-1285.
- Huang, Y.G., Gou, R., Diao, Y.S., Yin, Q.H., Fan, W.X., Liang, Y.P., Chen, Y., Wu, M., Zang, L., Li, L., Zang, J., Cheng, L., Fu, P., & Liu, F., 2014, Charlson Comorbidity Index Helps Predict the Risk of Mortality for Patients with Type 2 Diabetic Nephropathy, *Journal of Zhejiang University Science*, 15(1): 58-66.
- Ikawati, Z., 2007, *Farmakoterapi Penyakit Sistem Pernafasan*, 65-72, Pustaka Adipura, Yogyakarta.
- Imaizumi, Y., Eguchi, K., & Kario, K., 2014, Lung Disease and Hypertension, *Pulse*, 2(1-4): 103-112.
- Jakovljevic, M., Lazic, Z., Verhaeghe, N., Jankovic, S., Gajovic, O., & Annemans, S., 2013, Direct Medical Cost of COPD Diagnosis and Treatment, Eastern vs Western of Serbia and Belgium, *Farmeconomia*, 14(4): 161-168.
- Jayani, E.F.Y., 2010, Analisis Biaya Rawat Jalan Pasien Diabetes Melitus Tipe 2 Peserta Askes yang Menggunakan Antidiabetik Oral di RSUP Dr. Soeradji Tirtonegoro Klaten Periode Januari-Juni 2009, Skripsi, Fakultas Farmasi Universitas Sanata Dharma, Yogyakarta.
- Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2013, *Pedoman Penerapan Kajian Farmakoekonomi*, 1-3, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia (Kemenkes RI), 2016, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 76 Tahun 2016 Tentang Pedoman Indonesian Case Base Groups (INA-CBG) dalam Pelaksanaan Jaminan Kesehatan Nasional*, 13, Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kruti, D.P., Tarachand, L., & Kartik, S., 2014, Economic Burden in Direct Cost of Chronic Obstructive Pulmonary Disease at a Tertiary Care Teaching

- Hospital: A Prospective Observational Cohort Study, *Indian Journal of Pharmacy Practice*, 7(3): 61-68.
- Leader, D., 2020, *A Comprehensive Guide to COPD Complications*, <https://www.verywellhealth.com/image-gallery-of-copd-complications-914689>, 31 Oktober 2022.
- Lemeshow, S., Hosmer, D.W., Klar, J., & Lwanga, S.K., 1997, *Besar Sampel dalam Penelitian Kesehatan*, UGM Press, Yogyakarta.
- Mannino, D.M., Higuchi, K., Yu, T.C., Zhou, H., Li, Y., Tian, H., & Suh, K., 2015, Economic Burden of COPD in the Presence of Comorbidities, *Chest*, 148(1): 138-150.
- Mosenifar, Z., 2022, *Chronic Obstructive Pulmonary Disease (COPD)*, <https://emedicine.medscape.com/article/297664-overview>, 31 Oktober 2022.
- Nurfadhilah, A., 2017, Analisis Biaya dan Kesesuaian Biaya Riil dengan Tarif INA-CBGs pada Pasien Penyakit Paru Obstruktif Kronis Peserta JKN Rawat Inap di BBKPM Surakarta, Skripsi, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Ogan, N., Gunay, E., Baha, A., Candar, T., & Akpınar, E. E., 2020, The Effect of Serum Electrolyte Disturbances and Uric Acid Level on the Mortality of Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease, *Turkish Thoracic Journal*, 21(5): 322-328.
- Perhimpunan Dokter Paru Indonesia (PDPI), 2011, *PPOK (Penyakit Paru Obstruktif Kronis): Diagnosis dan Penatalaksanaan*, Perhimpunan Dokter Paru Indonesia, Jakarta.
- Poole, P.J., 2006, Role of Mucolytics in the Management of COPD, *International Journal of COPD*, 1(2): 123-128.
- Puspitasari, R.F., 2021, Analisis Biaya Pasien Gastritis Rawat Inap di RSUD Kota Madiun, Skripsi, Prodi S1 Farmasi Stikes Bhakti Husada Mulia, Madiun.
- Putri, F., 2009, Analisis Biaya Penyakit Paru Obstruksi Kronis Pasien Rawat Inap RSUD Dr. Moewardi Surakarta Berdasarkan Jenis Pembiayaan Periode

- Tahun 2008, Tesis, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Rychlik, R., 2002, *Strategies in Pharmacoeconomics and Outcomes Research*, 16, The Haworth Press, New York.
- Sugiyono, 2018, *Metode Penelitian Kuantitatif, Kualitatif, dan R&D*, Alfabeta, Bandung.
- Sulastomo, 2000, *Manajemen Kesehatan*, 16, PT Gramedia Pustaka Utama, Jakarta.
- Torabipour, A., Hakim, A., Angali, K.A., Dolatshah, M., & Yusofzadeh, M., 2016, Cost Analysis of Hospitalized Patients with Chronic Obstructive Pulmonary Disease: A State-Level Cross-Sectional Study, *Tanaffos*, 15(2): 75-82.
- Vijayan, V.K., 2013, Chronic Obstructive Pulmonary Disease, *Indian Journal of Medical Research*, 137(2): 251-269.
- Vogenberg, F.R., 2001, *Introduction to Applied Pharmacoeconomics*, 4-5, 197-199, McGraw Hill, New York.
- Wacker, M.E., Jorres, R.A., Schulz, H., Heinrich, J., Karrasch, S., Karch, A., Koch, A., Peters, A., Leidl, R., Vogelmeier, C., & Holle, R., 2016, Direct and Indirect Cost of COPD and its Comorbidities: Result from the German Cosyconet Study, *Respiratory Medicine*, 111: 39-46.
- Walley, T., Haycox, A., & Boland, A., 2004, *Pharmacoeconomics*, 3-5, 9-10, Elsevier Sciences, London.
- WHO, 2010, *Options for Financing and Optimizing Medicines in Resource-Poor Countries*, <https://apps.who.int/iris/handle/10665/85708>, 31 Oktober 2022.
- WHO, 2022, *Chronic Obstructive Pulmonary Disease*, [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)), 3 Oktober 2022.
- Wilson, J.P., & Rascati, K., 2001, *Pharmacoeconomic*, McGraw Hill, New York.
- Yunanda, E.E., 2018, Cost of Iness pada Pasien Penyakit Paru Obstruktif Kronis di RSUP Dr. Sardjito Yogyakarta, Skripsi, Fakultas Farmasi Universitas Gadjah Mada, Yogyakarta.
- Zhao, D., Liu, H., & Dong, P., 2019, A Meta Analysis of Antihypertensive Effect of Telmisartan versus Candesartan in Patients with Essential Hypertension, *Clinical and Experimental Hypertension*, 41(1): 75-79.